|Ph.D., 1997, Johns Hopkins University|
|Postdoctoral research: NIH and Memorial Sloan-Kettering Cancer Center|
|Office:||University of Massachusetts Medical School
364 Plantation Street, LRB-521
Worcester, MA 01605
Recent advances in oncology have demonstrated the efficacy of targeted therapeutics that inhibit key tumor-driving proteins or processes. Therefore, a primary goal of our laboratory is to elucidate the molecular mechanisms essential for the development and progression of pancreatic and hepatocellular carcinomas, with the goal of informing novel treatment strategies for these malignancies. We perform a combination of in vivo studies utilizing genetically engineered mouse models, cell culture phenotypic assays performed on primary cell cultures and cancer cell lines, and molecular biology and biochemical approaches to address these questions.
1. mTORC2 function in pancreatic tumorigenesis
2. Dissection of miR-17~92 and miR-106b~25 in pancreatic tumorigenesis
3. KLF6 target genes involved in hepatocellular carcinoma (HCC) dissemination
4. Involvement of the Notch signaling pathway in HCC metastasis
5. DNPH1 as a therapeutic target in solid tumors
same as lab rotations.